{"id":18843,"date":"2024-05-26T20:59:22","date_gmt":"2024-05-26T18:59:22","guid":{"rendered":"https:\/\/tirzepatyd.eu\/?post_type=product&p=18843"},"modified":"2026-04-19T11:19:58","modified_gmt":"2026-04-19T09:19:58","slug":"glp-3-retatrutide-4mg-vial","status":"publish","type":"product","link":"https:\/\/tirzepatyd.eu\/en\/shop-product\/glp-3-retatrutide-4mg-vial\/","title":{"rendered":"Triple G 4 mg vial GLP3"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

GLP-3 Retatrutide - what is it?<\/h2>

GLP-3 Retatrutide is a synthetic research peptide developed as a novel multi-receptor agonist. Its structure is based on an amino acid chain (about 39-41 amino acids) designed to simultaneously activate GLP-1, GIP and glucagon receptors. This combination of mechanisms translates into Multidirectional effects on appetite regulation, energy metabolism and glucose metabolism<\/strong>, making retatrutide a particularly promising compound in the context of obesity therapy. The structure of the molecule incorporates modifications that increase metabolic stability, including the attachment of a lipid chain that enables binding to albumin and prolongs the drug's duration of action in the body, promoting the convenience of use and long-lasting weight reduction effect<\/strong>. Just as Semaglutide<\/a> i Tirzepatide<\/a>, retatrutide belongs to a group of incretin receptor peptide agonists used in research to treat obesity and metabolic disorders<\/span><\/p>

GLP-3 Retatrutide is a peptide being developed for the treatment of obesity and type 2 diabetes. <\/span>It is a type of GLP-1, GIP and glucagon receptor agonist. <\/b>It acts on various biological mechanisms that regulate appetite, glucose metabolism and insulin secretion. Above all, this makes it effective for weight reduction and blood sugar control. Unlike other peptides of this type, the product shows even more effective action towards weight loss.\u00a0<\/span><\/p>

See also Orforglipron GLP1 reagent in capsules 5mg\/60caps<\/a><\/p>

GLP-3 Retatrutid<\/b> AND obesity research?<\/b><\/h2>

GLP-3 Retatrutide<\/b> is a modern peptide tested for obesity treatment<\/a>. It works by simultaneously affecting several hormone receptors in the body, which makes it different from many other products for obesity. Here's how it affects the body:<\/span><\/p>

  1. GLP-1 (glucagon-like peptide-1). <\/b>First, sthymulates insulin secretion and inhibits glucagon secretion, which consequently helps regulate blood sugar levels. In addition, it affects the satiety center in the brain, reducing appetite.<\/span><\/li>
  2. GIP (glucose-dependent insulinotropic polypeptide).\u00a0<\/b>It helps increase insulin secretion after eating, which also helps control blood glucose levels. When combined with GLP-1, it synergistically enhances weight loss effects.<\/span><\/li>
  3. Glucagon Receptor.\u00a0<\/b>Stimulation of this receptor helps increase the body's energy expenditure, which promotes weight loss.<\/span><\/li><\/ol>

    GLP-3 is thus a multifunctional peptide that simultaneously acts on several mechanisms regulating metabolism, appetite and energy expenditure. This holistic approach consequently may lead to more effective and sustainable treatment of obesity compared to drugs that act on single areas related to metabolism.<\/span><\/p>

    Also check out the Retatrutide GLP3 PEN reagent.<\/a><\/p>

    GLP-3 Retatrutide - observations from research studies<\/h2>

    Available publications<\/a> scientific and analyses of data from preclinical and clinical studies indicate that retatrutide, as a triple agonist of GLP-1, GIP and glucagon receptors, exhibits a number of biological properties relevant to studies of metabolic regulation and energy balance. Key observations reported in the scientific literature are summarized below.<\/p>

    Changes in body weight in the study populations<\/strong><\/p>

    In clinical trials conducted with retatrutide, significant weight changes were observed, particularly in groups receiving higher study doses. According to an analysis of clinical data described in a Medscape article (German edition), in selected study populations, average weight reductions reaching approximately 20-25% were reported over follow-up periods of up to 48 weeks. These results distinguished retatrutide from other incretin agonists and became the subject of extensive comparative analyses in the scientific literature.<\/p>

    Effects on glucose metabolism<\/strong><\/p>

    Activation of GLP-1 and GIP receptors is associated with improvements in glycemic control parameters observed in studies. The mechanism includes glucose-dependent modulation of insulin secretion and reduction of excessive glucagon secretion.The Medscape article highlights that retatrutide showed significant effects on metabolic parameters related to glucose metabolism, which was observed in parallel with changes in body weight in the study cohorts.<\/p>

    Modulation of mechanisms that regulate appetite<\/strong><\/p>

    In research models, the effects of retatrutide on central satiety pathways have been described, resulting in reduced energy supply. This phenomenon represents an important area of research into the neurohormonal regulation of appetite. Medscape analysis indicates that simultaneous activation of several hormone receptors<\/strong> may account for a more comprehensive effect on appetite regulation compared to single- or dual-receptor agonists.<\/p>

    Changes in metabolic parameters<\/strong><\/p>

    Other metabolic indicators, such as lipid profile, blood pressure and selected cardiovascular risk markers, were also analyzed during the study. The publications cited by Medscape noted favorable trends in some of the metabolic parameters, but the authors stress the need for further long-term studies to fully evaluate these observations.<\/p>

    Impact on energy expenditure<\/strong><\/p>

    Stimulation of the glucagon receptor, which is part of the triple mechanism of action of retatrutide, has been linked to increased energy expenditure and mobilization of energy substrates. This mechanism is an important area of research on energy balance and metabolic adaptation. The Medscape article noted that. glucagon receptor agonism component<\/strong> may play an important role in the observed metabolic changes, distinguishing retatrutide from classical incretin agonists.<\/p>

    GLP-3 Retatrutide - summary<\/h3>

    Retatrutide (LY3437943) is a synthetic peptide that is a triple agonist of GLP-1, GIP and glucagon receptors, and is the subject of preclinical and clinical studies in the area of energy metabolism and glucose regulation. The compound exhibits multidirectional effects on mechanisms regulating energy balance, appetite and glucose metabolism, as reflected in observations reported in the scientific literature. Its pharmacodynamic profile, resulting from structural modifications, makes retatrutide an important target for the study of complex incretin pathways.<\/p>

    \"GLP-3<\/a><\/p>

    Source:<\/a><\/p>

    Product intended for scientific research and laboratory analysis. All articles and information on this site are for informational and educational purposes only.<\/strong><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

    Retatrutide is a new-generation research peptide associated with processes affecting appetite, metabolic rate and energy balance in the body. Due to its wide range of effects, it is often seen as part of innovative concepts related to weight control. It stands out for its advanced characteristics and modern approach to metabolism.<\/p>","protected":false},"featured_media":31137,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false},"product_brand":[],"product_cat":[124,109,15],"product_tag":[136],"class_list":{"0":"post-18843","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-produkty-w-fiolce","7":"product_cat-triple-g","8":"product_cat-laboratory-research","9":"product_tag-fiolka","11":"first","12":"instock","13":"shipping-taxable","14":"purchasable","15":"product-type-variable"},"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18843","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/comments?post=18843"}],"version-history":[{"count":33,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18843\/revisions"}],"predecessor-version":[{"id":35476,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product\/18843\/revisions\/35476"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media\/31137"}],"wp:attachment":[{"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/media?parent=18843"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_brand?post=18843"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_cat?post=18843"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/tirzepatyd.eu\/en\/wp-json\/wp\/v2\/product_tag?post=18843"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}